Clinical Trial Technologies for Improving Equity and Inclusion in Cardiovascular Clinical Research

Approximately one-third of clinical trials fail to meet their recruitment goals, which can cause costly delays to sponsors and compromise the scientific integrity and generalizability of a trial. Inadequate recruitment and retention of patient groups who have the disease under investigation may prod...

Full description

Saved in:
Bibliographic Details
Published inCardiology and Therapy Vol. 12; no. 2; pp. 215 - 225
Main Authors Broadwin, Cassandra, Azizi, Zahra, Rodriguez, Fatima
Format Journal Article
LanguageEnglish
Published Cheshire Springer Healthcare 01.06.2023
Springer
Adis, Springer Healthcare
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Approximately one-third of clinical trials fail to meet their recruitment goals, which can cause costly delays to sponsors and compromise the scientific integrity and generalizability of a trial. Inadequate recruitment and retention of patient groups who have the disease under investigation may produce insufficient medical knowledge about the therapeutic effects of drugs or products for the population at large. It is essential to address these issues to ensure that certain groups are not unduly subjected to disproportionate risks or denied the benefits of research. This commentary will present opportunities for clinical trialists to use emerging technologies and decentralized approaches to improve clinical trial recruitment, mitigate disparities, and improve individual and population-level outcomes within cardiovascular medicine.
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
ISSN:2193-8261
2193-6544
DOI:10.1007/s40119-023-00311-y